Want to buy for someone else? You can purchase a token at check out.
Overview
The increased emphasis on pain management to improve functionality and quality of life has contributed to significantly more opioid prescriptions. Their availability led to widespread misuse across the nation. This course will address regulation and misuse of opioids and evidence-based management of chronic pain.
Goals and Learning Outcomes
- Discuss chronic pain and opioid use in the U.S.
- Review the regulatory influences and evidence-based guidelines associated with prescribing controlled substances for pain management.
- Describe evaluation and monitoring of the patient with pain.
- Identify pharmacologic and non-pharmacologic pain management strategies.
Course Details
Course Originally Released on : 2/9/2023
REL-ACU-0-OCPM
Accreditations
NURSES
In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Provider approved by the California Board of Registered Nursing, CEP#13791


Relias LLC reports to CEBroker for the following boards (Provider # 50-1489): Arkansas State Board Of Nursing, District Of Columbia Board Of Nursing, Florida Board Of Nursing, Georgia Board Of Nursing, Kansas State Board of Nursing, Kentucky Board of Nursing, Michigan Board of Nursing, Mississippi Board of Nursing, New Hampshire Board of Nursing, New Mexico Board Of Nursing, North Dakota Board of Nursing, South Carolina Board Of Nursing and West Virginia Board Of Registered Nurses
Please check the licenses/certifications section under my account (after logging in) to make sure you have entered a valid license number. This information is required for correct reporting of your course completions to CE Broker.
Disclosures
None of the planners/faculty, unless otherwise noted, for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
